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Beta-blockers with in-
trinsic sympathomimetic 
activity (acebutolol, alpre-
nolol, oxprenolol, pindo-
lol) appear to be ineff ective 
for migraine prevention.4
Amitriptyline works 
better than propranolol 
for some migraines
Amitriptyline is the most often studied anti-
depressant and the only one with consistent 
support for effi  cacy in preventing migraine. A 
1981 trial found amitriptyline to be more ef-
fective than propranolol in mixed migraine-
tension-type headache, whereas propranolol 
was more eff ective for migraine alone.5 
Some support for ﬂ uoxetine,
none for similar drugs
Limited evidence exists for the use of fl uox-
etine, 20 mg daily. A small 1999 study of pa-
tients with migraine without aura found a 57% 
reduction in total pain index—a value based 
on pain intensity and hours of headache per 
month—with fl uoxetine compared with an in-
signifi cant 31% reduction with placebo.6 
No evidence from controlled trials sup-
ports the use of fl uvoxamine, paroxetine, ser-
traline, phenelzine, venlafaxine, mirtazapine, 
trazodone, or bupropion.4 
Divalproex sodium, 
sodium valproate are effective
Divalproex sodium and sodium valproate 
show strong, consistent evidence of effi  cacy; 
they may be particularly useful for patients 
with prolonged or atypical migraine aura.4 
Initial studies of delayed-release divalproex at 
doses ranging from 500 to 1500 mg daily found 
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EVIDENCE-BASED ANSWER
A Beta-blockers without intrinsic sympathomimetic  activity, amitriptyline, divalproex sodium/sodium 
valproate, and topiramate are the most eff ective drugs for 
preventing episodic migraine (strength of recommendation: 
A, multiple, well-designed, randomized controlled trials 
[RCTs]). 
Evidence summary
Many medications have been evaluated for 
migraine prophylaxis. However, very few head-
to-head trials of more than 2 drugs have been 
published, and no recent meta-analyses of 
available drug classes have been performed. 
Th e most commonly evaluated outcome is a 
50% reduction in headache frequency.
Propranolol and timolol 
offer consistent prevention
Propranolol and timolol have consistently 
demonstrated effi  cacy for preventing episodic 
migraine. In a 1991 meta-analysis, proprano-
lol resulted in a 44% reduction in the head-
ache index—a composite score that takes into 
account both intensity and duration—com-
pared with a 14% reduction for placebo.1 
Less evidence supports 
other beta-blockers
Atenolol, metoprolol, and nadolol have dem-
onstrated a moderate eff ect, but less evidence 
exists to support their use.2 A recent trial 
comparing metoprolol and nebivolol demon-
strated a positive response—defi ned as a 50% 
reduction in headache frequency—to each 
drug at 14 weeks (57% of metoprolol-treated 
and 50% of nebivolol-treated patients), but 
noted that nebivolol was better tolerated.3 
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that 44% of divalproex-treated patients re-
ported a 50% reduction in migraine frequen-
cy, compared with 21% in the placebo group 
(number needed to treat [NNT]=4).7 
A more recent study of the extended-
release form of divalproex sodium demon-
strated a 4-week reduction in headache rate 
to 1.2 from a baseline of 4.4, compared with 
a decrease of 0.6 for placebo (95% confi dence 
interval [CI] of treatment diff erence, 0.2-1.2).8 
Topiramate may decrease frequency 
as much as propranolol
Topiramate has signifi cantly reduced the mean 
frequency of episodic migraine at doses of 100 
to 200 mg daily and also improved second-
ary end points, including number of migraine 
days per month, use of acute medication, and 
daily activity.9 One study found that topiramate 
100 mg daily had comparable effi  cacy to pro-
pranolol 160 mg daily; both drugs decreased 
monthly migraine frequency to 1.6 from a base-
line of 4.9 with topiramate and 5.1 with pro-
pranolol (95% CI for the pair-wise diff erence of 
topiramate minus propranolol, −0.58 to 0.60).10
Anticonvulsants also reduce 
migraine frequency
A 2004 Cochrane review of anticonvulsant 
drugs for migraine prophylaxis found that 
anticonvulsants, as a class, reduce migraine 
frequency by about 1.3 attacks per 28 days 
when compared with placebo (based on 
10 trials [N=902]). When analyzing data on 
relative frequency of migraines, data from 13 
trials (N=1773) were combined and showed 
that anticonvulsants more than doubled the 
number of patients with a 50% or greater de-
crease in migraine frequency relative to pla-
cebo (relative risk=2.25; 95% CI, 1.79-2.84; 
NNT=3.9; 95% CI, 3.4-4.7).11
Other drugs to keep on your radar
Agents available in the United States that have 
at least limited evidence supporting their use 
to prevent episodic migraine include gaba-
pentin, lisinopril, candesartan, memantine, 
ribofl avin, magnesium, feverfew, coenzyme 
Q10, butterbur, and melatonin. 
Drugs so far proved ineff ective in pre-
venting episodic migraine include clonidine, 
carbamazepine, clonazepam, vigabatrin, ox-
carbazepine, zonisamide, lamotrigine, nife-
dipine, and acetazolamide. Botulinum toxin 
type A given by intramuscular injection in the 
head and neck region has demonstrated limit-
ed effi  cacy in chronic headache disorders, but 
doesn’t prevent episodic migraine.12
Amitriptyline is 
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TABLE
Recommended drugs for migraine prophylaxis13
Drug Dose Comments
Propranolol 80-240 mg/d May cause fatigue. When used in combination with 
rizatriptan, give a lower dose of rizatriptan.
Timolol 20-30 mg/d As with propranolol, may cause fatigue.
Avoid β-blockers in patients with 
asthma or Raynaud’s disease.
Amitriptyline 25-150 mg/d Drowsiness, weight gain, and signiﬁ cant anticholinergic 
adverse events are common.
Divalproex sodium;
Sodium valproate
500-1500 
mg/d;
800-1500 
mg/d
Side effects include nausea, drowsiness, weight gain, hair loss, 
and tremor. Hepatotoxicity, pancreatitis, and hyperammonemia 
have been reported rarely. Pregnancy category D.
Topiramate 100-200 mg/d Paresthesia is the most common adverse event; fatigue, 
nausea, anorexia, and cognitive symptoms are less common. 
Carbonic anhydrase inhibition may cause metabolic acidosis.
Acute myopia and angle closure glaucoma are rare events.
CONTINUED
Recommendations
Th e 2000 guidelines of the American Association 
of Neurology address Group 1 (fi rst-line) drugs 
and Group 2 drugs:
❚ Group 1 drugs (medium to high effi  -
cacy, good strength of evidence, and a range 
of severity [mild to moderate] and frequency 
[infrequent to frequent] of side eff ects) include 
amitriptyline, divalproex sodium, proprano-
lol, and timolol. 
❚ Group 2 drugs (lower effi  cacy than 
Group 1, or limited strength of evidence, and 
mild to moderate side eff ects) include aspirin 
(but not combination products), atenolol, feno-
profen, feverfew, fl urbiprofen, fl uoxetine, ga-
bapentin, guanfacine, ketoprofen, magnesium, 
mefenamic acid, metoprolol, nadolol, naprox-
en, nimodipine, verapamil, and vitamin B2.13
Topiramate was still under study when the 
guidelines were released and wasn’t approved 
by the US Food and Drug Administration for 
migraine prophylaxis until 2004. Th e 2000 
guidelines are undergoing revision.                         
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